The Use of Bromocriptine for Peripartum Cardiomyopathy after Twin Delivery via Oocyte Donation

Nagisa Morikawa¹, Takaharu Nakayoshi¹, Hanae Yoshimura¹, Megumi Watanabe¹, Jun Kumanomido¹, Aya Furusho¹, Daisuke Fukui¹, Kazuko Eto¹, Norifumi Nishida¹, Michihide Nishihara¹, Chizuko A. Kamiya² and Yoshihiro Fukumoto¹

Abstract:
Peripartum cardiomyopathy (PPCM) is rare but life-threatening. We herein report the case of a 48-year-old woman with PPCM after oocyte donation and delivery of twins. Two weeks after delivery, she suffered from severe symptoms of heart failure [orthopnea, New York Heart Association (NYHA) class IV, pulmonary edema and a reduced left ventricular ejection fraction of 18%]. Although standard heart failure therapy was effective for diminishing the congestion, it was not sufficient to improve her symptoms or left ventricular systolic dysfunction. During admission, we added bromocriptine. A year later after the onset, she was in a good state with an improved left ventricular systolic function.

Key words: peripartum cardiomyopathy, assisted reproductive technique, bromocriptine

(Intern Med 58: 541-544, 2019)
(DOI: 10.2169/internalmedicine.1537-18)

Introduction
Peripartum cardiomyopathy (PPCM) is a rare form of cardiomyopathy occurring in women between one-month antepartum and five-months postpartum (1, 2). Although the precise mechanisms remain unknown, several risk factors or associated conditions have been suggested, including older age (1), multiparity (3), lower parity (4), infectious diseases, autoimmune diseases (5), pregnancy-associated hypertensive diseases (4, 6), cesarean section, volume overload, multifetal pregnancies (4), and the use of tocolytic therapy (4).

For women with diminished ovarian reserve, premature ovarian failure, genetic disorders and surgical menopause, oocyte donation, which was first introduced in the early 1980s, improves the chances of achieving pregnancy and live birth (7-9). In the United States and other countries, assisted reproductive technologies (ARTs) including oocyte donation are increasingly used to overcome infertility. There were approximately 20,000 attempts at achieving pregnancy with the use of oocyte donation in the United States in 2015 (10). ART using donor eggs or embryos is much more common among older women than among younger women and the percentage of cycles performed with donor eggs increases sharply after 40 years of age. Likewise, the number of pregnancies achieved using ART has been increasing in line with the aging of pregnant women, even in Japan (11, 12). However, the prevalence of obstetric complications of ART, including PPCM, has not obviously been reported. We herein report a rare case of a patient, who developed PPCM after donor oocyte gestation and delivery. This case report was approved by the Ethics Committee of Kurume University Hospital and the patient gave her informed consent for the publication of this report.

Case Report
A 48-year-old Japanese woman was admitted to our hospital due to dyspnea and orthopnea two weeks after an elective cesarean section after achieving pregnancy by ART using donor oocytes (three frozen-thawed embryos were transferred and live births were achieved). It was her first preg-
nancy and she had twins. She had no pre-existing cardiovascular disease, gestational hypertension, proteinuria or preeclampsia during pregnancy. At the 38th week of gestation, a planned cesarean section was performed without problems and both newborns were delivered in a good condition. She was free from cardiovascular symptoms after delivery.

On admission, chest X-ray demonstrated pulmonary edema (Fig. 1A). Electrocardiography (ECG) showed sinus tachycardia (heart rate, 120 beats/min) with poor R-wave progression in V1-V4 and premature ventricular contraction (PVC) (Fig. 1B). Echocardiography revealed severe left ventricular dysfunction with a reduced left ventricular ejection fraction (LVEF) of 18% (severe hypokinesis outside of the lateral region) and left ventricular dilatation [left ventricular end diastolic diameter (LVEDD) 59 mm] (Supplementary material 1). A blood test showed an elevated level of N-terminal pro-brain natriuretic peptide (NTpro-BNP) (8,298 pg/mL) and normal levels of troponin T (0.021 ng/mL) and creatine kinase (CK) (129 U/L). We diagnosed her with PPCM and transferred her to our intensive care unit (ICU). On the 6th day, we started anti-coagulation therapy using edoxaban (30 mg, once a day), due to a suspected venous thromboembolism. She was treated with intravenous nitroglycerin (1 mg/min), furosemide (20 mg, intravenous, twice a day), spironolactone (200 mg, intravenous, once a day) and non-invasive positive pressure ventilation (NIPPV), to which she responded very well. In the chronic phase, she received an angiotensin-converting enzyme (ACE)-inhibitor (enalapril maleate 5 mg twice a day) and a beta-blocker (bisoprolol fumarate 1,25 mg once a day). Despite optimal therapy and decreased NTpro-BNP levels (156 pg/mL), her symptom remained New York Heart Association (NYHA) class III and her left ventricular (LV) contractility was still reduced (LVEF 23.8%). Thus, after receiving ethics committee approval from Kurume University Hospital and obtaining written informed consent, we started the administration of a dopamine-D2-receptor agonist, bromocriptine (5 mg/day for 2 weeks and 2.5 mg/day for the next 6 weeks) (13) on the 41st day after cesarean section (25th day after the onset of heart failure) in addition to cardiac rehabilitation. On day 28, we performed cardiac catheterization, which indicated normal hemodynamics, normal coronary angiography, and a reduced LVEF of 34% (Fig. 2A). Cardiac biopsy indicated mild cardiac fibrosis without inflammatory cells, which was also compatible with PPCM (Fig. 2B). She was discharged to return home on the 44th day and bromocriptine was continued for a total of 8 weeks. In an examination at an outpatient clinic, she was in a good state (NYHA class II, NTpro-BNP levels; 152 pg/mL 3 months later and 90 pg/mL one year later). Echocardiography showed a smaller LVEDD (53 mm both 3 months and one year later) and an improved LVEF (44% 3 months later and 47% one year later) (Supplementary material 2, 3).

**Discussion**

Generally, several risk factors, including older age (1) and multifetal pregnancies (4), as were present in this case, are known to increase the risk of PPCM; these factors are also apparently associated with ART. Thus, it is possible that PPCM often occurs in women who have received ART or that ART itself causes PPCM. A retrospective cohort of 36 women with PPCM by Shani et al. showed that 36% of PPCM patients conceived with in vitro fertilization (IVF) and that 16% of PPCM cases occurred in women who received ovum donation; this prevalence was significantly higher in comparison to controls without PPCM (14). In the cohort study, Shani et al. presented the demographics and the pregnancy characteristics (ART vs. non-ART PPCM subgroups), indicating that the ART group showed a higher maternal age and had a higher prevalence of primipara, multifetal pregnancies and cesarean delivery in comparison to the non-ART group. The cardiac function at the time of the diagnosis and the follow-up phase was comparable between the 2 subgroups. Nevertheless, the regression analyses of Shani et al. also demonstrated that ART was not an independent risk factor for PPCM, even after adjustment for
other risk factors (maternal age, parity and number of fetuses) (OR 1.802, 0.59-5.875) (14).

In contrast, some previous studies demonstrated that ART was associated with an increased risk of pregnancy complications (15-17). Levron, et al. (18) suggested that the rate of hypertensive diseases of pregnancy in donor oocyte (IVF-DO) recipients was significantly higher than that in patients who conceived with autologous oocytes (IVF-AO) (25% vs 10%). Interestingly, even after adjustment for maternal age, gravidity, parity, and the presence of chronic hypertension, oocyte donation was independently associated with a higher rate of hypertensive diseases of pregnancy (18). It has been hypothesized that preeclampsia might result from an abnormal maternal immune response to novel paternally derived fetal antigens (19-22) and the difference between IVF-DO and IVF-AO might support the immunologic theory. Future studies are necessary to investigate whether donor oocytes are potential risk factor for not only hypertensive disease but also PPCM.

In this case, we added bromocriptine to the optimal heart failure therapy. After bromocriptine therapy, the left ventricular systolic function of our patient improved. However, it is unclear whether or not this was a direct effect of bromocriptine. Whether the use of bromocriptine has a prognostic benefit in patients with PPCM remains controversial. Experimental studies have suggested that 16 kDa prolactin reduced the myocardial capillary density, reduced the cardiac function and promoted endothelial cell apoptosis (23-25). Then, the suppression of prolactin secretion by bromocriptine prevented PPCM in these mice (23). In a clinical pilot study, bromocriptine prevented the expected deterioration of LV dimensions and the systolic function when administered in addition to standard heart failure therapy to patients with subsequent pregnancy after known PPCM (13). However, concerns have been raised about the potential risk of cerebral and cardiovascular complications, such as stroke (26, 27), seizure (28), coronary artery thrombosis (28), and coronary artery vasospasm (29, 30). Caution is therefore needed in drawing conclusions about the effectiveness of bromocriptine in patients with PPCM. In fact, a recent prospective, randomized, and multicenter trial demonstrated that both long-term and short-term bromocriptine in addition to standard therapy for heart failure is associated with a high recovery rate and very low rate of adverse outcome in patients with severe forms of PPCM; in the studies, attention was paid to ensure sufficient anticoagulant therapy during treatment (31, 32). Indeed, bromocriptine is suspected to be associated with thrombotic events (32). Thus, anticoagulation therapy is recommended-at least at a prophylactic dose (32). The optimal dosage and duration of therapy to achieve the maximum cardioprotective effects still remains a matter of investigation. Further research is required to prove the efficacy of bromocriptine in the treatment of PPCM.

Conclusion

We reported the case of a woman with a history of ART who developed PPCM. Pregnant women who conceive via
ART should be carefully monitored to detect the onset of heart failure during pregnancy and in the peripartum period.

The authors state that they have no Conflict of Interest (COI).

References

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 44: 964-968, 1971.
2. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283: 1183-1188, 2000.
3. Fett JD, Carraway RD, Dowell DL, King ME, Pierre R. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 186: 1005-1010, 2002.
4. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111: 2050-2055, 2005.
5. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamooy N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 23: 301-324, 2002.
6. Wittlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol 176: 182-188, 1997.
7. Devroey P, Wisanto A, Camus M, et al. Oocyte donation in patients without ovarian function. Hum Reprod 3: 699-704, 1988.
8. Sills ES, Brady AC, Omar AB, Walsh DJ, Salma U, Walsh AP. IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister. Reprod Biol Endocrinol 8: 31, 2010.
9. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 376: 911-921, 2010.
10. Centers for Disease Control and Prevention American Society for Reproductive Medicine. Society for Assisted Reproductive Technology. 2015 Assisted Reproductive Technology National Summary. [Internet]. [cited 2018 May 13]. Available from: https://ww w.cdc.gov/art/pdf/2015-report/ART-2015-National-Summary-Report.pdf
11. Ministry of Health, Labour and Welfare. [Internet]. [cited 2018 May 13]. Available from: http://www.stat.go.jp/data/handbook/inde x.htm
12. Kashirn VA, Barad DH, Albertini DF, Darmon SK, Gleicher N. Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol 15: 6, 2017.
13. Sliwa K, Blauwet L, Tabarzadeh K, et al. Evaluation of coronaryctomie in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121: 1465-1473, 2010.
14. Shani H, Kuperstein R, Berlin A, Arad M, Goldenberg I, Simchen MJ. Peripartum cardiomyopathy-risk factors, characteristics and long-term follow-up. J Perinat Med 43: 95-101, 2015.
15. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singleton deliveries following in vitro fertilization: a meta-analysis. Obstet Gynecol 103: 551-563, 2004.
16. Schieve LA, Ferre C, Peterson HB, Macaluso M, Reynolds MA, Wright VC. Perinatal outcome among singleton infants conceived through assisted reproductive technology in the United States. Obstet Gynecol 103: 1144-1153, 2004.
17. Blazquez A, Garcia D, Rodriguez A, Vassena R, Figueras F, Vermaeve V. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J Assist Reprod Genet 33: 855-863, 2016.
18. Levron Y, Dvir M, Seqol I, et al. The ‘immunologic theory’ of preeclampsia revisited: a lesson from donor oocyte gestations. Am J Obstet Gynecol 211: 383.e1-383.e5, 2014.
19. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308: 1592-1594, 2005.
20. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2: 656-663, 2002.
21. Schuling GA, Koiter TR, Faus MM. Why pre-eclampsia? Hum Reprod 12: 2087-2091, 1997.
22. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 24: 147-158, 2009.
23. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128: 589-600, 2007.
24. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173: 219-238, 2002.
25. Tabrany SP, Sorlet CM, Rentier-Delrue F, et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 17: 1815-1823, 2003.
26. Iffy L, Lindenthal J, Mcardle JJ, Ganesh V. Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. IJr J Med Sci 32: 309-312, 1996.
27. Kim YS, Baek W, Kim J, Kim HY, Lee YJ. Delayed ischemic stroke associated with bromocriptine-induced reversible cerebral vasocconstriction syndrome. Neurol Sci 34: 409-411, 2013.
28. Loewe C, Dragovic LJ. Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. Am J Forensic Med Pathol 19: 258-260, 1998.
29. Hopp L, Weisse AB, Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol 12: 415-418, 1996.
30. Y-Hassan S, Jeremb T. Bromocriptine-induced coronary spasm caused acute coronary syndrome, which triggered its own clinical twin-Takotsubo syndrome. Cardiology 119: 1-6, 2011.
31. Hilfiker-Kleiner D, Haghiakia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomised study. Eur Heart J 38: 2671-2679, 2017.
32. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 38: 2680-2682, 2017.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/).